IOL Chemicals & Pharmaceuticals Files SEBI Compliance Certificate for Q3 FY26
IOL Chemicals and Pharmaceuticals Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018. This compliance filing is for the quarter ended December 31, 2025, and confirms the processing of physical share certificates for dematerialization.
This is a standard regulatory compliance filing that is expected from listed companies and does not provide any new material information that would significantly impact the company's stock price or operations.
The announcement is a routine compliance filing related to share certificate dematerialization and does not contain any information that would positively or negatively impact the company's stock.
IOL Chemicals and Pharmaceuticals Limited has submitted a certificate in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018. This certificate pertains to the quarter ended 31st December 2025.
The company received this certification from its Registrar and Share Transfer Agent, M/s. Alankit Assignment Limited. The certification confirms that physical share certificates received for dematerialization have been processed according to the regulations. Specifically, the securities were verified, the certificates were mutilated and cancelled, and the depository's name was updated as the registered owner in their records.
Alankit Assignments Limited has confirmed that the required certificate under Regulation 74(5) was submitted to the depositories and stock exchanges within the stipulated timeframe. The company has requested that this submission be taken on record.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.